MetaCap

SAB Biotherapeutics Inc. (SABS)

NASDAQ: SABSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

2.81-0.10 (-3.44%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SABS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$253.15M
EPS (TTM)
-$1.35
52-week range
2.44 – 5.15
Day range
2.64 – 2.88
Volume / Avg
874.57K / 633.60K
Beta
—

52-week range

$2.44$5.15

SABS stock today

Shares of SAB Biotherapeutics (SABS) finished lower on Nov 20 at $2.81, a drop of 3.44% or $0.10 per share, versus the S&P 500's 3.70% decline. Shares are 45.4% below their 52-week high of $5.15, set on Mar 12, 2026 and 15.2% above the 52-week low of $2.44, near the bottom of the past year's range. SABS is down 24.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 28.9%.

SAB Biotherapeutics has posted a net loss over the last twelve months (EPS of -$1.35), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About SAB Biotherapeutics

Company profile

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Samuel J. Reich
Headquarters
Miami Beach, FL
Employees
86
IPO year
2021
Website
sab.bio

Financial highlights

Full financials

In fiscal 2025, SAB Biotherapeutics generated $0 in revenue, down 100.0% from fiscal 2024, its first annual decline since 2024. Net income was $13.3 million. Diluted earnings per share came in at -$0.79.

SAB Biotherapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$0$1.32M$2.24M$23.90M$60.88M
Growth-100.00%-40.94%-90.63%-60.73%+10.21%
Net income$13.27M$-34.11M$-42.19M$-18.74M$-17.14M
EPS (diluted)$-0.79$-3.68$-7.64$-4.31$-0.63

Analyst forecast

Forecast

Consensus (11 analysts)

strong_buy

Avg. price target

$11.64+314.23%

  • Strong buy 1
  • Buy 10
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $6.00High $16.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.24 vs $-0.27
Surprise
+11.11%

SABS news

All SABS news

SAB Biotherapeutics peers

Health Care sector
SABS peer companies
CompanyPrice% ChgMarket capCompare
EDITEditas Medicine Inc.1.64-4.09%$253.12Mvs SABS
EIKNEikon Therapeutics Inc.4.74-0.42%$256.84Mvs SABS
OCGNOcugen Inc.0.7679+4.79%$260.55Mvs SABS
LXEOLexeo Therapeutics Inc.2.96+0.34%$245.05Mvs SABS
PLXProtalix BioTherapeutics Inc. (DE)2.90-5.23%$244.52Mvs SABS
AUTLAutolus Therapeutics plc ADR0.9073-7.38%$241.65Mvs SABS
AGMBAgomAb Therapeutics NV ADR5.45-3.02%$268.40Mvs SABS
KYTXKyverna Therapeutics Inc.4.26-2.52%$269.33Mvs SABS

Indexes, lists and sector

SAB Biotherapeutics stock FAQ

What is SAB Biotherapeutics's stock price today?

SABS last traded at $2.81 as of Nov 20, 4:00 PM EST, down 3.44% on the day. Prices are delayed at least 15 minutes.

Does SAB Biotherapeutics pay a dividend?

No. SAB Biotherapeutics does not currently pay a regular cash dividend.

Who is SAB Biotherapeutics's CEO?

Mr. Samuel J. Reich is the chief executive officer of SAB Biotherapeutics Inc., which has about 86 employees.

Has SABS ever split its stock?

Yes. The most recent SABS stock split was a 1-for-10 split on Jan 5, 2024.

What is the SABS 52-week high?

The 52-week high for SABS is $5.15 and the 52-week low is $2.44. The stock is currently 45.4% below its high.

Compare SABS